U.S. Insurance Stock News

SLB (SLB) is back in focus after a series of digital and AI centric announcements, including an expanded collaboration with NVIDIA and a three year enterprise platform agreement with Azule Energy in Angola. See our latest analysis for SLB. Despite a 3.68% one day share price pullback to US$51.53, SLB’s 90 day share price return of 33.67% and 1 year total shareholder return of 27.05% point to building momentum as recent AI and digital agreements keep the stock in focus. If you are tracking how...

If you are wondering whether Chord Energy's share price still offers value at current levels, it helps to step back and look at what the recent performance and valuation checks are really saying. The stock last closed at US$146.24, with returns of 11.8% over 7 days, 34.9% over 30 days, 54.5% year to date, and 36.6% over the past year. These moves have arrived alongside ongoing investor interest in the broader US energy sector. Companies like Chord Energy often draw attention when pricing,...

Wondering if JBS at around US$17.34 actually offers value or if the easy gains are gone? This breakdown will help you weigh what the current price might really reflect. The stock has delivered a 15.1% return over the last 7 days, 2.7% over the past 30 days, and 22.3% year to date, which has likely sharpened attention on both its potential and its risks. Recent coverage has focused on JBS as a major player in the global food and meat supply chain, with attention on topics such as industry...

Rayonier (NYSE:RYN) has appointed KPMG as its independent auditor for the 2026 fiscal year audit. The company will transition from its current auditor, Ernst & Young, as part of this change. Rayonier reported that the switch did not arise from disagreements on accounting practices or adverse audit opinions. For investors watching Rayonier at a share price of $20.6, the auditor change follows a challenging stretch for the stock. NYSE:RYN has seen a 17.8% decline over the past year and a...

If you are wondering whether SkyWater Technology's recent run still offers value, or if you might be late to the story, this article will walk through what the current price could be implying. The stock trades at US$26.18 after a 10.5% pullback over the last week and 11.1% over the last month, yet it still sits on a 16.7% year-to-date return and a 269.3% return over the past year. These moves come as SkyWater continues to attract attention as a specialized semiconductor foundry, with...

Wondering if Old National Bancorp at around US$21.48 is offering fair value or a potential mispricing opportunity? This article breaks down what the current share price might really be telling you. The stock has seen a 0.3% decline over the past week and a 7.0% decline over the past month, while still sitting on a 4.0% return over the last year and a 65.0% return over three years. This can signal changing views on both growth potential and risk. Recent coverage has focused on Old National...

McDonald’s Chief Sustainability & Social Impact Officer Beth Hart is scheduled to deliver a keynote at the Sustainability LIVE: The US Summit, outlining the company’s sustainability and social impact approach. Alongside the ESG focus, McDonald’s has announced senior leadership changes across operations, franchising, and transformation, affecting both domestic and global oversight. These developments reflect an updated leadership vision and public ESG positioning that are relevant for long...

If you are wondering whether Snowflake is priced fairly or if the current share price leaves room for upside, this article breaks down what the latest numbers say about value. Snowflake shares last closed at US$153.67, with returns of an 11.8% decline over 7 days, an 8.8% decline over 30 days and a 29.1% decline year to date, while the 1 year return sits at 5.1% and the 3 year return at 2.4%, compared to a 33.9% decline over 5 years. Recent headlines have focused on Snowflake's role in cloud...

Wondering whether Strategy's share price still reflects its true worth, or if recent volatility has opened up an opportunity. Strategy closed at US$121.44, with returns of a 12.1% decline over 7 days, a 6.2% decline over 30 days, a 22.7% decline year to date, and a 57.9% decline over 1 year, set against a very large 3 year return and a 68.5% gain over 5 years. These swings have kept Strategy on the radar of investors who are weighing long term gains against more recent pullbacks. Evergreen...

UBS recently named Cigna Group as a top healthcare pick, arguing that concerns around pharmacy benefit manager reform have largely been absorbed and that the company’s move to a rebate-free model has improved earnings visibility. The analysts also highlighted Cigna’s limited exposure to government reimbursement, its discount relative to peers, and the potential for share buybacks as key supports for the investment case. We’ll now examine how UBS’s view of Cigna as undervalued with improved...

Plains GP Holdings filed a new shelf registration for its Class A common shares. The filing gives the company flexibility to issue new equity securities in the future. The move is a material corporate action that can affect funding plans and existing shareholders. Plains GP Holdings (NasdaqGS:PAGP) last closed at $24.42, with the shares showing returns of 2.8% over the past week and 8.3% over the past month. Over longer periods, the stock has returns of 25.8% year to date and 24.1% over the...

Samsung and Advanced Micro Devices (NasdaqGS:AMD) signed a memorandum of understanding covering HBM4 memory supply and possible future foundry cooperation for AI chips. The agreement centers on Samsung providing HBM4 for AMD's MI455X AI GPUs, which are planned for its Helios rack scale AI infrastructure. The partnership points to tighter integration across memory and manufacturing for upcoming generations of AI hardware. AMD enters this announcement with a share price of $196.04 and a 1...

Damora Therapeutics recently overhauled its leadership, appointing former Arcus Biosciences executive Jennifer Jarrett as President and Chief Executive Officer and adding industry veterans Cameron Turtle and Mike Landsittel to its Board, while several directors resigned. This reshaping of the executive team brings together extensive biopharma operating, deal-making and capital markets experience, potentially influencing how Damora pursues future partnerships, financing and commercialization...

Cintas (CTAS) is back on investors’ radar after releasing third quarter results and lifting its fiscal 2026 outlook, including guidance for annual revenue of about US$11.21b to US$11.24b. See our latest analysis for Cintas. The guidance lift comes after a weak stretch for the share price, with a 30 day share price return of 16.14% and a year to date share price return showing an 8.77% decline. However, the 3 year total shareholder return of 50.27% and 5 year total shareholder return of 99.52%...

Agios Pharmaceuticals recently disclosed that, following a pre-supplemental New Drug Application meeting, it will seek U.S. accelerated approval for mitapivat in sickle cell disease and has already submitted a proposal for the required confirmatory trial, which is not expected to alter its previously issued operating expense guidance. An interesting aspect for investors is that the FDA has asked Agios to run a confirmatory trial with a new primary endpoint informed by RISE UP data and...

Cimpress (CMPR) has put a new capital return plan in focus, announcing a share repurchase program of up to US$200 million shortly after its previous buyback expired and its removal from the NASDAQ Internet Index. See our latest analysis for Cimpress. At a share price of US$72.75, Cimpress has delivered a 90 day share price return of 9.25% and a 1 year total shareholder return of 59.05%. The new US$200 million buyback plan keeps capital allocation in focus after its removal from the NASDAQ...

Recent share performance and business snapshot Celsius Holdings (CELH) has drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past week, month and past 3 months while the underlying business continues to generate revenue and earnings. The company operates in functional energy and hydration drinks, reporting US$2,515.3m in revenue and US$63.8m in net income, primarily from North America, and carries a market value of about...

Investors may be wondering if Akamai Technologies at around US$110 a share still offers value, or if most of the easy gains are already on the table. The stock closed at US$110.22, with a 3.7% decline over the last 7 days, a 12.0% gain over 30 days, 29.5% year to date, 36.9% over 1 year, 41.5% over 3 years, and 6.1% over 5 years. This gives you a wide range of recent return experiences to weigh up. Recent coverage has focused on Akamai's role as a key infrastructure player for content...

Recent share performance and business snapshot Occidental Petroleum (OXY) has drawn investor attention after a recent share price move, with the stock last closing at $66.24, set against a value score of 2 and an intrinsic discount estimate of 42.71%. See our latest analysis for Occidental Petroleum. The recent 1-month share price return of 24.79% and 90-day share price return of 59.77% point to strong positive momentum. The 1-year total shareholder return of 37.10% and 5-year total...

In recent weeks, gold prices have swung as easing U.S.–Iran tensions, a stronger U.S. dollar and profit‑taking offset concerns about the U.S.’s roughly US$42.00 trillion net fiscal deficit and rising Treasury yields, which together keep gold’s role as a hedge in focus for investors. As the world’s largest gold producer, Newmont has sat at the center of these shifting speculative flows into and out of gold, with its cost efficiencies and dividend profile drawing investors who are reassessing...

Over the last 7 days, the United States market has dropped 3.5%, yet it has seen a rise of 14% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these growth opportunities.

AbbVie’s Allergan Aesthetics unit is running its fourth annual CoolMonth promotion in April 2026, offering new patients discounts on CoolSculpting treatments. The company highlighted new aesthetics data at the American Academy of Dermatology meeting, including a next generation neurotoxin candidate. AbbVie reported emerging trends such as GLP-1 users entering the aesthetics segment and patient concerns about cost and unnatural looking results. For NYSE:ABBV, this CoolMonth campaign...

The United States market has experienced a 3.5% decline over the past week, yet it remains up by 14% over the last year with anticipated earnings growth of 15% annually in the coming years. In this fluctuating environment, identifying stocks that may be trading below their estimated worth can provide opportunities for investors seeking value amidst broader market trends.

If you are wondering whether AT&T's current price really reflects what you are getting as a shareholder, you are asking the right question. AT&T recently closed at US$28.78, with returns of 0.1% over 7 days, 2.7% over 30 days, 17.2% year to date and 6.2% over the last year. This gives you a useful starting point for judging value. Recent coverage around AT&T has focused on its role as a major U.S. telecom provider and how it fits into long term connectivity trends. This context helps frame...